Gene-Driven Adjuvant Therapy for NSCLC Leads to Big Improvement in DFS

(MedPage Today) — CHICAGO — Biomarker-driven adjuvant therapy for intermediate/high-risk non-small cell lung cancer (NSCLC) led to significantly longer disease-free survival (DFS) as compared with observation, a randomized trial showed.
DFS…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115810

Author :

Publish date : 2025-05-31 12:00:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

Gene-Driven Adjuvant Therapy for NSCLC Leads to Big Improvement in DFS

The Covid Inquiry Podcast: ‘I wasn’t the decision maker’

Sacituzumab or Chemo in First-Line TNBC: Which Is Better?

Related Posts

A crucial methane-tracking satellite has died in orbit

ACIP Members Show Inexperience, Lack of Understanding at First Meeting, Experts Say

Senate Passes Trump’s Tax Bill With $1 Trillion in Health Cuts

HHS Confirms Contracts With Springer Nature Have Been Terminated

DREAMM-20 Hints at a More Tolerable Path for BCMA-Targeted Therapy in Myeloma

Sleep and Alzheimer’s; NIH Cuts to Brain Research; Novel CTE Report

A crucial methane-tracking satellite has died in orbit

ACIP Members Show Inexperience, Lack of Understanding at First Meeting, Experts Say

Senate Passes Trump’s Tax Bill With $1 Trillion in Health Cuts

HHS Confirms Contracts With Springer Nature Have Been Terminated

DREAMM-20 Hints at a More Tolerable Path for BCMA-Targeted Therapy in Myeloma

Sleep and Alzheimer’s; NIH Cuts to Brain Research; Novel CTE Report

Physical Activity and Rehabilitation in Duchenne Muscular Dystrophy

RFK Jr.’s Mass Firings Likely Unlawful and Must Be Halted, Judge Says

Categories

Archives